Repositioning Candidate Details
| Candidate ID: | R0997 |
| Source ID: | DB06376 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | CHGN111 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase. Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative stress. It was under investigation until approximately 2007. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in skin infections/disorders. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase. Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative stress. Compared to free radical scavengers or other detoxifying agents they directly modulate reactive oxygen species production and detoxification at an early stage to prevent damage and stop disease initiation as well as progression. Such drugs with a new mechanism of action allows Chronogen to target different pathological situations from acute and severe conditions like reperfusion-injury to more chronic situations in cardiovascular and central nervous system diseases. |
| Targets: | Dual specificity protein kinase CLK1 |
| Inclusion Criteria: | Therapeutic strategy associated |
